foxj1b Antibody

What is FOXJ1 and what cellular functions does it regulate?

FOXJ1 (Forkhead box protein J1) is a 50-kDa transcription factor belonging to the Forkhead-box (FOX) family of winged-helix transcription factors. It plays essential roles in several biological processes:

• Motile ciliogenesis: FOXJ1 is specifically required for the formation of motile cilia, activating transcription of genes that mediate cilia assembly, such as CFAP157 .

• DNA binding: It recognizes specific DNA consensus sequences (5'-HWDTGTTTGTTTA-3' or 5'-KTTTGTTGTTKTW-3', where H is not G, W is A or T, D is not C, and K is G or T) .

• Transcriptional activation: FOXJ1 activates the transcription of various ciliary proteins in the developing brain and lung .

• Immune regulation: It modulates germinal center formation and Th1 activation by repressing NFκB through IκBβ induction .

• Autoimmunity: FOXJ1 has been suggested to antagonize autoimmune reactions such as systemic lupus erythematosus and rheumatoid arthritis .

In multiciliated cells, FOXJ1 acts as a master regulator of motile ciliogenesis, and its expression serves as a reliable marker for cells that will develop motile cilia .

How does foxj1b differ from FOXJ1, and what is its specific role in zebrafish?

In zebrafish, foxj1b is one of the orthologs of mammalian FOXJ1. While mammals typically have a single FOXJ1 gene, teleost fish often possess multiple paralogs due to genome duplication events. Recent studies have shown that:

• Expression pattern: In zebrafish, foxj1b is predominantly expressed in multiciliated cells (MCCs) .

• Structural markers: MCCs expressing foxj1b can be identified by labeling with antibodies against glutamylated-tubulin, one of the building blocks of motile cilia .

• Functional conservation: Despite some evolutionary divergence, foxj1b maintains the core function of regulating motile ciliogenesis, similar to its mammalian counterpart.

• Reporter systems: Advanced genetic tools including foxj1a-TagRFP knock-in lines have been developed to track expression patterns in live zebrafish .

The presence of these paralogs in zebrafish provides researchers with unique opportunities to study the evolution and specialization of FOXJ1 functions in vertebrates.

What is the tissue-specific expression pattern of FOXJ1/foxj1b?

FOXJ1/foxj1b exhibits a distinct tissue-specific expression pattern:

In mouse olfactory epithelium, immunostaining reveals that FOXJ1 is detected in mature olfactory sensory neurons, as demonstrated by overlap with OMP (olfactory marker protein) signals. Importantly, FOXJ1 is predominantly localized to the nuclei of these cells, consistent with its role as a transcription factor .

What criteria should researchers prioritize when selecting a FOXJ1/foxj1b antibody?

When selecting a FOXJ1/foxj1b antibody for research applications, consider these critical criteria:

• Species specificity: Ensure the antibody recognizes your species of interest. For zebrafish foxj1b studies, antibodies may require additional validation due to limited commercial options specifically developed for this ortholog.

• Antibody type: Monoclonal antibodies (e.g., clone 2A5 or EPR21874) offer high specificity but potentially lower sensitivity compared to polyclonal alternatives .

• Application compatibility: Verify validation for your specific application:

  • The 2A5 monoclonal antibody has been validated for western blotting, immunohistochemical staining of formalin-fixed paraffin-embedded tissue sections, and immunocytochemistry .

  • The EPR21874 rabbit monoclonal antibody (ab235445) has been validated primarily for IHC-P applications with human, mouse, and rat samples .

• Epitope location: For transcription factors like FOXJ1, antibodies recognizing conserved domains may work across species boundaries.

• Validation standards: Prioritize antibodies with rigorous validation data, including knockout controls, as observed in studies where no FOXJ1 immunostaining was detected in the olfactory epithelium of FOXJ1 knockout mice .

• Cross-reactivity profile: Review potential cross-reactivity with other FOX family proteins, particularly important when studying zebrafish where multiple paralogs exist.

How can researchers definitively validate FOXJ1/foxj1b antibody specificity?

Rigorous validation of antibody specificity is essential for reliable research outcomes. Recommended validation approaches include:

• Genetic controls: The gold standard for validation is testing the antibody in tissues from knockout models. As documented in the literature, anti-FOXJ1 antibodies show no immunostaining in the olfactory epithelium of FOXJ1 knockout mice, confirming specificity .

• Multiple antibody comparison: Using antibodies from different clones that target distinct epitopes to verify consistent staining patterns.

• Correlation with expression data: Compare antibody staining patterns with mRNA expression profiles from in situ hybridization or RNA-sequencing.

• Western blot analysis: Confirm that the antibody detects a protein of the expected molecular weight (approximately 50 kDa for FOXJ1) .

• Fixed versus frozen tissue comparison: Some epitopes may be better preserved in frozen sections versus fixed tissues.

• Peptide competition assays: Pre-incubating the antibody with immunizing peptide should abolish specific binding.

• Subcellular localization: FOXJ1, being a transcription factor, should demonstrate predominantly nuclear localization, as observed in imaging studies .

A comprehensive validation strategy employing multiple methods provides the highest confidence in antibody specificity and experimental results.

What are the optimal conditions for immunohistochemical detection of FOXJ1/foxj1b?

Successful immunohistochemical detection of FOXJ1/foxj1b requires careful optimization of several parameters:

• Fixation protocols:

  • Adult tissues: Anesthesia with ketamine/xylazine followed by cardiac perfusion with ice-cold PBS, then 4% paraformaldehyde (PFA) .

  • Neonatal tissues: Anesthesia on ice, decapitation, and immersion fixation in ice-cold fixative .

  • Critical note: FOXJ1 detection in mouse olfactory epithelium specifically requires fixation in 1% PFA, rather than the standard 4% PFA .

• Antigen retrieval methods:

  • FOXJ1 detection often requires heat-activated retrieval using Tris/EDTA buffer (1 mM EDTA, 0.05% Tween 20, pH 8.0) .

  • High-pressure treatment for 20 minutes in a pressure cooker has been reported as effective .

• Antibody dilutions and incubations:

  • For EPR21874 rabbit monoclonal antibody: 1/2000 dilution for human tissues .

  • For 2A5 monoclonal antibody: 1-10 μg/mL range, requiring careful titration for optimal performance .

  • Secondary antibody selection: HRP-conjugated secondaries for chromogenic detection or fluorophore-conjugated antibodies for fluorescence imaging.

• Controls and counterstaining:

  • Positive controls: Include tissues with known high FOXJ1 expression (e.g., respiratory epithelium).

  • Negative controls: FOXJ1-knockout tissues are ideal when available.

  • Counterstaining: Hematoxylin for brightfield imaging; DAPI for fluorescence microscopy.

• Special considerations for zebrafish:

  • Whole-mount protocols require extended permeabilization steps.

  • Consider using transgenic reporter lines (e.g., foxj1a-TagRFP knock-in) as complementary approaches .

What methodological approaches are most effective for co-localization studies with FOXJ1/foxj1b?

Co-localization studies provide valuable insights into FOXJ1/foxj1b function and regulation. Effective approaches include:

• Multi-color immunofluorescence:

  • FOXJ1 + ciliary markers: Co-staining with antibodies against acetylated tubulin or glutamylated-tubulin helps correlate FOXJ1 expression with ciliary structures .

  • FOXJ1 + cell-type markers: For example, co-staining with OMP in olfactory epithelium identifies mature OSNs expressing FOXJ1 .

  • Nuclear markers: Co-staining with nuclear envelope markers or DAPI confirms the nuclear localization of this transcription factor.

• Sequential immunostaining protocols:

  • When antibodies are derived from the same species, sequential staining with intermediate blocking steps can prevent cross-reactivity.

  • Antibody elution or stripping protocols between rounds of staining.

• Advanced imaging approaches:

  • Confocal microscopy: Essential for accurate co-localization analysis by eliminating out-of-focus signal.

  • Deconvolution: Improves resolution and signal-to-noise ratio.

  • Super-resolution techniques: Methods like structured illumination microscopy (SIM) or stimulated emission depletion (STED) microscopy provide enhanced spatial resolution.

• Quantitative analysis:

  • Colocalization coefficients (Pearson's, Manders') provide objective measures of spatial correlation.

  • Single-cell analysis of expression levels across cell populations.

• Complementary approaches:

  • Proximity ligation assays (PLA) for detecting protein-protein interactions involving FOXJ1.

  • Combined RNA in situ hybridization with protein immunodetection.

What protocol modifications enhance western blot detection of FOXJ1/foxj1b?

Western blot detection of FOXJ1/foxj1b can be optimized with these specialized protocol modifications:

• Sample preparation:

  • Nuclear extraction protocols are strongly recommended as FOXJ1 is predominantly nuclear.

  • Protease inhibitor cocktails are essential to prevent degradation.

  • Validated positive controls include mouse tracheal epithelial cells and testes .

• Gel electrophoresis considerations:

  • 10-12% polyacrylamide gels effectively resolve the approximately 50 kDa FOXJ1 protein.

  • Loading adequate protein (typically 20-50 μg of nuclear extract) ensures detection of less abundant transcription factors.

• Transfer optimization:

  • PVDF membranes may provide better results than nitrocellulose for some FOXJ1 antibodies.

  • Transfer efficiency verification using reversible staining (Ponceau S).

• Blocking and antibody incubation:

  • 5% non-fat dry milk or BSA in TBST is typically effective.

  • For the 2A5 monoclonal antibody, the recommended concentration range is 1-10 μg/mL .

  • Overnight primary antibody incubation at 4°C often yields optimal results.

• Detection strategies:

  • Enhanced chemiluminescence with extended exposure times may be necessary for low abundance.

  • For quantitative analysis, consider fluorescence-based detection systems.

  • Signal amplification systems for detecting low expression levels.

• Multiplexing strategies:

  • Stripping and reprobing for housekeeping genes.

  • Dual-color detection systems using different fluorophores for simultaneous detection of multiple proteins.

Following these optimized protocols significantly improves the likelihood of successful FOXJ1/foxj1b detection and quantification in western blot applications.

How can researchers address weak or inconsistent FOXJ1/foxj1b immunostaining?

When faced with weak or inconsistent FOXJ1/foxj1b immunostaining, consider these systematic approaches:

• Fixation optimization:

  • Critical finding: For mouse olfactory epithelium, 1% PFA fixation has been specifically demonstrated as optimal for FOXJ1 detection, rather than standard 4% PFA .

  • Test different fixation durations to balance epitope preservation with tissue morphology.

  • Consider alternative fixatives or combination protocols that might better preserve the FOXJ1 epitope.

• Enhanced antigen retrieval:

  • Heat-induced epitope retrieval using Tris/EDTA buffer (pH 8.0) with high-pressure treatment is effective for FOXJ1 detection .

  • Systematically compare different antigen retrieval methods and durations.

  • Enzymatic retrieval methods may provide alternatives when heat-based methods are insufficient.

• Signal amplification systems:

  • Tyramide signal amplification (TSA) can dramatically increase detection sensitivity.

  • Polymer-based detection systems often provide enhanced sensitivity over traditional methods.

  • Multi-layer detection strategies using biotin-streptavidin systems.

• Antibody optimization:

  • Titrate primary antibody concentration across a broad range (typically 1-10 μg/mL for FOXJ1 antibodies) .

  • Extend primary antibody incubation (overnight at 4°C).

  • Test multiple antibody clones targeting different epitopes.

• Technical considerations:

  • Ensure sections are not over-deparaffinized, which can cause antigen loss.

  • Use freshly prepared buffers and reagents.

  • Consider tissue pretreatment with protein crosslink breakers.

  • Optimize incubation temperature (4°C, room temperature, or 37°C).

• Validation approaches:

  • Compare results with mRNA expression data to confirm expected expression patterns.

  • Use positive control tissues with known high FOXJ1 expression.

What strategies effectively reduce background in FOXJ1/foxj1b immunofluorescence?

High background can obscure specific FOXJ1/foxj1b staining. These strategies help maximize signal-to-noise ratio:

• Blocking optimization:

  • Extended blocking (2+ hours or overnight) with 5-10% normal serum.

  • Addition of 0.1-0.3% Triton X-100 to blocking solution.

  • Use of commercial background reducers containing proprietary blocking proteins.

  • Species-matched blocking serum (from the same species as the secondary antibody).

• Antibody handling:

  • Centrifugation of antibody solutions before use to remove aggregates.

  • Pre-adsorption of primary antibodies with tissue powder.

  • Titration to determine optimal concentration (signal-to-noise optimization).

  • Use of F(ab) or F(ab')2 fragments instead of whole IgG to reduce Fc-mediated binding.

• Washing protocols:

  • Increased wash duration and number of wash steps.

  • Addition of 0.05-0.1% Tween-20 or Triton X-100 to wash buffers.

  • Elevated salt concentration in wash buffers (up to 0.5M NaCl).

• Fluorescence-specific considerations:

  • Use of Sudan Black B (0.1-0.3%) to reduce autofluorescence.

  • Sodium borohydride treatment to quench aldehyde-induced fluorescence.

  • Careful selection of fluorophores to avoid spectral overlap with tissue autofluorescence.

  • Confocal microscopy with narrow bandwidth detection.

• Secondary antibody optimization:

  • Highly cross-adsorbed secondary antibodies.

  • Use of directly conjugated primary antibodies to eliminate secondary antibody background.

  • Titration of secondary antibody concentration.

• Tissue-specific treatments:

  • Autofluorescence quenching protocols tailored to the specific tissue type.

  • Special considerations for highly vascular or pigmented tissues.

These optimization strategies should be systematically tested to identify the most effective combination for your specific experimental system.

How can FOXJ1/foxj1b antibodies be leveraged for studying ciliopathies?

FOXJ1/foxj1b antibodies provide powerful tools for investigating ciliopathies - disorders arising from ciliary dysfunction:

• Diagnostic applications:

  • Quantitative assessment of FOXJ1 expression in patient samples compared to controls.

  • Evaluation of motile cilia abundance and morphology in relation to FOXJ1 expression.

  • Correlation of FOXJ1 expression patterns with disease severity or progression.

• Mechanistic investigations:

  • ChIP-seq analysis to identify dysregulated FOXJ1 target genes in ciliopathy models.

  • Co-immunoprecipitation studies to identify altered protein interactions in disease states.

  • Subcellular localization studies to detect abnormal FOXJ1 trafficking or nuclear import.

• Therapeutic development applications:

  • High-content screening using FOXJ1 immunofluorescence as a readout for compounds that modulate expression or activity.

  • Assessment of gene therapy approaches aimed at restoring FOXJ1 function.

  • Monitoring treatment efficacy through quantitative measurement of FOXJ1 expression and ciliary restoration.

• Disease modeling approaches:

  • FOXJ1 immunostaining in patient-derived organoids or iPSC-derived ciliated cells.

  • Correlation of genetic variants with altered FOXJ1 expression or localization.

  • Zebrafish models using foxj1b reporters combined with antibody validation.

The combination of genetic approaches with antibody-based detection provides comprehensive insights into disease mechanisms and potential therapeutic avenues for ciliopathies.

What advanced imaging techniques enhance FOXJ1/foxj1b localization studies?

Advanced imaging technologies significantly enhance the precision and information content of FOXJ1/foxj1b localization studies:

• Super-resolution microscopy approaches:

  • Structured illumination microscopy (SIM) improves spatial resolution to ~100 nm.

  • Stimulated emission depletion (STED) microscopy provides resolution down to ~30-80 nm.

  • Single-molecule localization methods (PALM/STORM) achieve molecular-scale precision.

  • Applications: Precise subnuclear localization of FOXJ1, potential identification of transcriptional hubs or nuclear microdomains.

• Multi-dimensional imaging:

  • Light sheet microscopy for rapid, low-phototoxicity volumetric imaging.

  • Tissue clearing techniques (CLARITY, iDISCO, CUBIC) for whole-organ imaging.

  • 3D reconstruction of FOXJ1+ cell distribution across entire tissues.

  • Applications: Mapping the complete distribution of FOXJ1-expressing cells in developmental contexts.

• Live-cell approaches:

  • CRISPR-mediated endogenous tagging, as demonstrated with the foxj1a-TagRFP knock-in system .

  • Fluorescent protein fusions for real-time dynamics.

  • Applications: Monitoring FOXJ1 expression and localization during differentiation or in response to stimuli.

• Multi-modal correlative approaches:

  • Correlative light and electron microscopy (CLEM) linking FOXJ1 expression to ultrastructure.

  • Combined protein and RNA detection to correlate transcription factor presence with target gene expression.

  • Applications: Connecting molecular mechanisms to structural outcomes.

• Quantitative imaging:

  • Fluorescence correlation spectroscopy (FCS) for protein dynamics.

  • Fluorescence recovery after photobleaching (FRAP) for mobility measurements.

  • Number and brightness analysis for oligomerization studies.

  • Applications: Understanding the dynamic behavior of FOXJ1 in living systems.

These advanced techniques provide unprecedented insights into FOXJ1 biology beyond what conventional imaging approaches can reveal.

How do post-translational modifications affect FOXJ1/foxj1b antibody recognition?

Post-translational modifications (PTMs) can significantly impact antibody recognition of FOXJ1/foxj1b and provide insights into regulatory mechanisms:

• Known FOXJ1 modifications:

  • Phosphorylation: Multiple sites affecting DNA binding and transcriptional activity.

  • Ubiquitination: Regulating protein stability and turnover.

  • Acetylation: Potentially affecting nuclear localization and chromatin interaction.

• Epitope masking effects:

  • Antibodies targeting regions containing PTM sites may show differential recognition depending on modification status.

  • Conformational changes induced by PTMs can mask or expose epitopes distant from the modification site.

  • Protein-protein interactions may block antibody access to specific epitopes.

• Experimental approaches to assess PTM impact:

  • Phosphatase treatment of samples before immunoblotting.

  • Comparison of multiple antibodies targeting different epitopes.

  • Use of PTM-specific antibodies in parallel with general FOXJ1 antibodies.

  • Cellular treatments that modulate specific modifications (kinase inhibitors, deacetylase inhibitors).

• PTM-specific detection strategies:

  • Phospho-specific antibodies for studying activation states.

  • Proximity ligation assays to detect specific modified forms in tissue contexts.

  • Mass spectrometry following immunoprecipitation to identify modification patterns.

• Functional significance:

  • Different cellular contexts may feature distinct PTM patterns.

  • Disease states may exhibit altered modification profiles.

  • Understanding PTM-specific detection provides insights into regulatory mechanisms.

Researchers should consider how PTMs might affect antibody recognition when interpreting experimental results, particularly when comparing different physiological or pathological states.